Epidermolysis Bullosa
B-VEC FDA Label Expansion for DEB: What It Means for Patients and CliniciansÂ
In May 2023, the FDA approved beremagene geperpavec (B-VEC, Vyjuvek®),
September 17, 2025
In May 2023, the FDA approved beremagene geperpavec (B-VEC, Vyjuvek®),
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
